From the Department of Pathology, Northwestern Memorial Hospital, Chicago, Illinois.
Arch Pathol Lab Med. 2019 Jan;143(1):23-29. doi: 10.5858/arpa.2017-0242-RA. Epub 2018 Apr 13.
CONTEXT.—: The incidence of anal cancer in the United States is on the rise in high-risk populations. The anal Papanicolaou test (APT) is advocated as a screening tool, in addition to digital rectal examination and high-resolution anoscopy.
OBJECTIVE.—: To review our experience and the current literature to create, in cooperation with clinicians, a standardized screening and treatment algorithm given our large volume of APTs.
DATA SOURCES.—: All APTs collected between January 2013 and June 2015 were reviewed and correlated with follow-up/concurrent biopsy diagnoses, and clinical and social history. In total, 1417 APTs were performed on 1185 patients and APT results were as follows: 17.4% (247 of 1417) unsatisfactory; 27.9% (395 of 1417) negative; 19.5% (276 of 1417) atypical squamous cells of undetermined significance (ASC-US); 24.1% (342 of 1417) low-grade squamous intraepithelial lesion (LSIL); 3.6% (51 of 1417) atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (HSIL) (ASC-H); and 7.5% (106 of 1417) HSIL. In total 376 cases (26.5%) had concurrent/follow-up biopsy. Review of all unsatisfactory cases with squamous intraepithelial lesion (SIL) on biopsy showed LSIL in 19.2% (5 of 26). Anal Papanicolaou test with cytologic abnormality (ASC-US+) had an 83.8% (315 of 376) rate of biopsy-proven disease, and sensitivity was higher (92%) for high-grade anal intraepithelial neoplasia or worse (AIN2+). Overall detection of AIN2+ using ASC-US+ showed specificity of 26%, negative predictive value of 92%, and positive predictive value of 26%.
CONCLUSIONS.—: Anal cytology has a high abnormal rate (54.7%) and sensitivity but poor correlation with histologic grade. High unsatisfactory rate indicates need for improvement in sampling with 68.4% of cases having SIL on biopsy. Multidisciplinary effort led to improvements in sampling, cytologic interpretation, and development of a standardized management algorithm.
在美国,高危人群中肛门癌的发病率呈上升趋势。除了数字直肠检查和高分辨率肛门镜检查外,肛门巴氏涂片检查(APT)也被推荐作为一种筛查工具。
与临床医生合作,回顾我们的经验和当前文献,制定一个标准化的筛查和治疗方案,鉴于我们进行了大量的 APT。
回顾了 2013 年 1 月至 2015 年 6 月期间收集的所有 APT,并将其与随访/同期活检诊断、临床和社会史相关联。共有 1185 名患者进行了 1417 次 APT,结果如下:17.4%(247/1417)不满意;27.9%(395/1417)阴性;19.5%(276/1417)非典型鳞状细胞意义不明确(ASC-US);24.1%(342/1417)低级别鳞状上皮内病变(LSIL);3.6%(51/1417)非典型鳞状细胞,不能排除高级别鳞状上皮内病变(ASC-H);7.5%(106/1417)HSIL。共有 376 例(26.5%)进行了同期/随访活检。对所有活检有鳞状上皮内病变(SIL)的不满意病例进行回顾,发现 LSIL 占 19.2%(26/136)。细胞学异常(ASC-US+)的 APT 有 83.8%(315/376)的活检阳性率,且对高级别肛门上皮内瘤变或更严重的病变(AIN2+)的敏感性更高(92%)。总的来说,使用 ASC-US+检测 AIN2+的特异性为 26%,阴性预测值为 92%,阳性预测值为 26%。
肛门细胞学异常率高(54.7%),敏感性高,但与组织学分级相关性差。高不满意率表明需要改进取样,68.4%的病例活检有 SIL。多学科努力提高了取样、细胞学解释能力,并制定了标准化的管理方案。